Juan W Valle, Arndt Vogel, Crystal S Denlinger, Aiwu Ruth He, Li-Yuan Bai, Rashida Orlova, Eric Van Cutsem, Jorge Adeva, Li-Tzong Chen, Radka Obermannova, Thomas J Ettrich, Jen-Shi Chen, Harpreet Wasan, Allicia C Girvan, Wei Zhang, Jiangang Liu, Chunlao Tang, Philip J Ebert, Amit Aggarwal, Samuel C McNeely, Brian A Moser, Joana M Oliveira, Roberto Carlesi, Richard A Walgren, Do-Youn Oh
BACKGROUND: Biliary tract cancers are aggressive, rare, gastrointestinal malignancies with a poor prognosis; approximately half of patients with these cancers survive for less than 1 year after diagnosis with advanced disease. We aimed to evaluate the efficacy and safety of ramucirumab or merestinib in addition to first-line cisplatin-gemcitabine in patients with locally advanced or metastatic biliary tract cancer. METHODS: We did a randomised, double-blind, phase 2 study at 81 hospitals across 18 countries...
October 2021: Lancet Oncology